相关实验视频

Updated: Sep 18, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

老年患有转移性荷尔蒙敏感前列腺癌的患者是否受益于三重或双重疗法? 一个网络元分析

Susu Zhou¹, Parissa Alerasool², Noriko Kishi³

¹Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside-West, New York, NY; Division of Hematology and Medical Oncology, Department of Medicine, SUNY Upstate Medical University, Syracuse, NY.

Clinical genitourinary cancer

|June 22, 2025

概括

对于患有转移性荷尔蒙敏感前列腺癌的老年男性,用达洛胺,抗雄激素剥夺疗法和多塞的三重疗法显著改善了整体存活率. 这种组合疗法在当前治疗选择中为这一群体提供了最明显的益处.

科学领域:

在瘤学瘤学.
临床药理学临床药理学

背景情况:

针对雄激素受体轴向 (ARAT) 药物的扩大批准为转移性激素敏感前列腺癌 (mHSPC) 提供了新的治疗选择.
在老年mHSPC患者中强化治疗策略的临床益处仍然不确定.

研究的目的:

评估与ARAT药物和/或dcetaxel结合的抗雄激素剥夺疗法 (ADT) 在老年mHSPC患者中的疗效.
为了在这个特定的人群中比较不同治疗强化策略的整体存活期 (OS).

主要方法:

系统的文献搜索随机对照试验 (RCT) 在70岁或75岁以上的mHSPC患者中.
网络元分析以间接比较ADT与ARAT药物和/或多塞塔结合的疗效.
评估的主要终点是整体存活率 (OS).

主要成果:

与单独使用ADT (HR:0.47) 和ADT + docetaxel (HR:0.61) 相比,达罗胺 + ADT + docetaxel的三重疗法显示出显著的OS益处.
阿比拉 + ADT + 多塞塔克塞尔没有显示出统计学上显著的OS益处.
基于达洛胺的三倍疗法在疗效方面排名最高 (P值:0.90),表明老年mHSPC患者的优异结果.

结论:

使用达洛胺,ADT和多塞塔克塞尔的三重疗法是mHSPC老年患者最有效的治疗选择,显示出最大的OS益处.
需要进一步的研究来评估三重剂方案在这个人群中的特定毒性,以优化治疗决策.

关键词:

安卓素剥夺疗法是一种安卓素剥夺治疗.素受体轴准剂的作用.处理强化加大处理.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...